Impact of Chronic Obstruction Pulmonary Disease on Survival in Patients with Advanced Stage Lung Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy

被引：3
作者：
Chiu, Kuo-Chin [1 ]
Lin, Wei-Chun [1 ]
Chang, Chia-Lun [2 ,3 ]
Wu, Szu-Yuan [4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
机构：
[1] Lo Hsu Med Fdn, Lotung Poh Ai Hosp, Dept Internal Med, Div Chest, Yilan 256, Taiwan
[2] Taipei Med Univ, Wan Fang Hosp, Dept Hematooncol, Taipei 110, Taiwan
[3] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 110, Taiwan
[4] Asia Univ, Coll Med & Hlth Sci, Dept Food Nutr & Hlth Biotechnol, Taichung 413, Taiwan
[5] Lo Hsu Med Fdn, Lotung Poh Ai Hosp, Big Data Ctr, Yilan 256, Taiwan
[6] Lo Hsu Med Fdn, Lotung Poh Ai Hosp, Div Radiat Oncol, Yilan 256, Taiwan
[7] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung 413, Taiwan
[8] Lo Hsu Med Fdn, Lotung Poh Ai Hosp, Canc Ctr, Yilan 256, Taiwan
[9] Fu Jen Catholic Univ, Grad Inst Business Adm, Taipei 242062, Taiwan
[10] Taipei Med Univ, Taipei Municipal Wan Fang Hosp, Ctr Reg Anesthesia, Taipei 110, Taiwan
[11] Taipei Med Univ, Taipei Municipal Wan Fang Hosp, Ctr Pain Med, Taipei 110, Taiwan
来源：
CANCERS | 2021年 / 13卷 / 13期
关键词：
lung cancer; squamous cell carcinoma; chronic obstruction pulmonary disease; concurrent chemoradiotherapy; survival; INTENSITY-MODULATED RADIOTHERAPY; PHASE-I TRIAL; RADIATION PNEUMONITIS; CONFORMAL RADIOTHERAPY; DOSE-ESCALATION; CANCER-PATIENTS; III TRIAL; COPD; CHEMOTHERAPY; RISK;
D O I：
10.3390/cancers13133231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Simple Summary No data are available regarding the effect of chronic obstruction pulmonary disease (COPD) and COPD with acute exacerbation (COPDAE) on survival in patients with lung squamous cell carcinoma (SCC) receiving definitive concurrent chemoradiotherapy (CCRT). This study is the first to examine the survival impact of COPD in patients with lung SCC receiving definitive CCRT. COPD and its severity are significant independent risk factors for all-cause mortality in patients with stage IIIA-IIIB lung SCC receiving definitive CCRT. Hospitalization for COPDAE within 1 year before CCRT is the significant independent risk factor for lung cancer death in the patients with stage IIIA-IIIB lung SCC receiving definitive CCRT. Background: To date, no data are available regarding the effect of chronic obstruction pulmonary disease (COPD) and COPD with acute exacerbation (COPDAE) on survival in patients with lung squamous cell carcinoma (SCC) receiving definitive concurrent chemoradiotherapy (CCRT). Patients and methods: We enrolled 3986 patients with clinical stage IIIA-IIIB, unresectable lung SCC, who had received standard definitive CCRT, and categorized them into two groups based on their COPD status to compare overall survival outcomes. We also examined the effects of COPD severity (0, 1, or >= 2 hospitalizations for COPDA within 1 year before CCRT). Results: In the inverse probability of treatment weighting (IPTW)-adjusted model, the adjusted hazard ratio (aHR) (95% confidence interval (CI)) of all-cause death for COPD was 1.04 (1.01, 1.16), compared no COPD in patients with stage IIIA-IIIB lung SCC receiving definitive CCRT. In the IPTW-adjusted model, the aHRs (95% CIs) of 1 and >= 2 hospitalizations for COPDAE within 1 year before CCRT were 1.32 (1.19, 1.46) and 1.81 (1.49, 2.19) respectively, compared with no hospitalization for COPDAE. Conclusion: COPD and its severity are significant independent risk factors for all-cause death in patients with stage IIIA-IIIB lung SCC receiving definitive CCRT. Hospitalization for COPDAE within 1 year before CCRT is the significant independent risk factor for lung cancer death in the patients with stage IIIA-IIIB lung SCC receiving definitive CCRT.
引用
收藏
页数：15
相关论文
共 54 条
  • [1] Concurrent cisplatin, etoposide, and chest radiotherapy in Pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019
    Albain, KS
    Crowley, JJ
    Turrisi, AT
    Gandara, DR
    Farrar, WB
    Clark, JI
    Beasley, KR
    Livingston, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) : 3454 - 3460
  • [2] Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
    Allan, Victoria
    Ramagopalan, Sreeram, V
    Mardekian, Jack
    Jenkins, Aaron
    Li, Xiaoyan
    Pan, Xianying
    Luo, Xuemei
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (09) : 603 - 614
  • [3] [Anonymous], 2019, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report
  • [4] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [5] High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine after Induction with Gemcitabine and Carboplatin
    Arrieta, Oscar
    Gallardo-Rincon, Dolores
    Villarreal-Garza, Cynthia
    Michel, Rosa M.
    Astorga-Ramos, Alma M.
    Martinez-Barrera, Luis
    de la Garza, Jaime
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (07) : 845 - 852
  • [6] Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of national cancer institute of Canada clinical trials group trials
    Asmis, Timothy R.
    Ding, Keyue
    Seymour, Lesley
    Shepherd, Frances A.
    Leighl, Natasha B.
    Winton, Tim L.
    Whitehead, Marlo
    Spaans, Johanna N.
    Graham, Barbara C.
    Goss, Glenwood D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 54 - 59
  • [7] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
    Auperin, Anne
    Le Pechoux, Cecile
    Rolland, Estelle
    Curran, Walter J.
    Furuse, Kiyoyuki
    Fournel, Pierre
    Belderbos, Jose
    Clamon, Gerald
    Ulutin, Hakki Cuneyt
    Paulus, Rebecca
    Yamanaka, Takeharu
    Bozonnat, Marie-Cecile
    Uitterhoeve, Apollonia
    Wang, Xiaofei
    Stewart, Lesley
    Arriagada, Rodrigo
    Burdett, Sarah
    Pignon, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2181 - 2190
  • [8] Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
    Austin, Peter C.
    Stuart, Elizabeth A.
    [J]. STATISTICS IN MEDICINE, 2015, 34 (28) : 3661 - 3679
  • [9] Prognostic Significance of Grading in Lung Adenocarcinoma
    Barletta, Justine A.
    Yeap, Beow Y.
    Chirieac, Lucian R.
    [J]. CANCER, 2010, 116 (03) : 659 - 669
  • [10] Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol
    Belani, CP
    Choy, H
    Bonomi, P
    Scott, C
    Travis, P
    Haluschak, J
    Curran, WJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5883 - 5891
123456